Deciphera gets FDA nod for Qinlock to treat fourth-line gastrointestinal stromal tumour

This article was originally published here

The FDA approval allows Qinlock, a kinase inhibitor, to treat adult patients with advanced GIST who have secured prior treatment with three or more kinase inhibitors, including imatinib.

The post Deciphera gets FDA nod for Qinlock to treat fourth-line gastrointestinal stromal tumour appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply